

AUTHOR INDEX

Volume 44

July to December 1991

- Abdel-Razik, M., 419
 Acosta, A.A., 657
 Al-Azzony, M., 419
 Albornoz, H., 235
 Al-Kholy, G., 419
 Allam, G., 431
 Alloush, M., 431
 Alvarez, F., 473, 481
 Anwar, M., 141
 Applebaum-Bowden, D., 113
 Araujo, M.D., 191
 Ashwell, E., 223
 Aydinlik, S., 589
 Bahmondes, L., 217
 Bailey, P.E., 191
 Baird, D.T., 89
 Ball, M.J., 223
 Bandivdekar, A.H., 559
 Bardin, C.W., 393
 Basdevant, A., 599
 Blaabjerg, J., 517
 Borkar, D.M., 245
 Brache, V., 473, 481
 Brännström, M., 445
 Brockwell, N.J., 21
 Cardenas, M., 45
 Castilla, E.E., 173
 Cattanach, J.F., 607
 Champion, C.B., 141
 Chandra, K., 99
 Cheng, J., 367
 Chi, I-c, 341, 573
 Chitlange, S.M., 245
 Clark, G.F., 657
 Conard, J., 599
 Conn, P.M., 667
 Coria, I., 541
 Coutinho, E., 473
 Cowan, G.M., 667
 Croxatto, H.B., 393
 Dalton, H.P., 21
 D'Antona, N., 155
 deCastro, B.M., 191
 deCastro, M.P.P., 191
 Degrelle, H., 599
 De la Cruz, D.L., 61
 DeLeo, V., 155
 Demers, L.M., 113
 deVoogd, W.S., 107
 Dhar, J.D., 461
 Dhawan, V., 99
 Díaz, J., 217, 473, 481
 Díaz, M., 235
 Díaz, M., 217
 Diaz, M.M., 473
 Diaz, R., 31
 Díaz, S., 393
 Diaz, S., 473, 481
 Dobbie, M.S., 649
 Doseburg, W.H., 277
 Dunson, T.R., 31, 489
 El Mahgoub, S., 473
 Eskes, T.K.A.B., 277
 Espinosa de los Monteros, A., 541
 Etchepareborda, J.J., 589
 Fahmy, K., 419, 431
 Farr, G., 141
 Fatinikun, T., 45
 Faundes, A., 217, 473
 Ferrer, M.A., 31
 Flynn, A., 125
 Fraser, H.M., 667
 Fuziwarra, J.L., 61
 Gabiño, F., 541
 Gallardo, E., 533
 Ganguly, N.K., 99
 Garza-Flores, J., 45, 62
 Githui, E.K., 311
 Gillmer, M.D.G., 223
 Giwa-Osagie, O.F., 83
 Glasier, A.F., 89
 Gobran, F., 431
 Gopalkrishnan, K., 245
 Grønlund, B., 517
 Griffin, M., 639
 Gu, Z., 367
 Gupta, I., 99
 Harris, G.S., 31
 Haukkamaa, M., 269
 Hazari, K.T., 245
 Heikinheimo, O., 269
 Hernandez, L., 45
 Hodgen, G.D., 657
 Hutapea, H., 141
 Indian Council of Medical
 Research Task Force on
 Hormonal Contraception, 409
 Janowitz, B., 191, 623
 Jivasak-Apimas, S., 183
 Johri, R.K., 549
 Jones, A.R., 649

CONTRACEPTION

- Josefsson, G-B, 445
- Källén, B., 173
- Kaufmann, J., 589
- Kelly, R.W., 89
- Kemara, K.P., 141
- Kesserü, E.v., 235, 589
- Khairy, M., 431
- Khan, F.Y., 505
- Koide, S.S., 559
- Konje, J.C., 163
- Kringelbach, M., 173
- Kumar, T.C.A., 245
- Ladipo, O.A., 163
- Lancaster, P.A.L., 173
- Lanzetta, D., 155
- Laurikka-Routti, M., 269
- Lenker, R., 113
- Levenson, I., 505
- Liljestrang, J., 445
- Lunn, S.F., 667
- Luo, H., 367
- Mahony, M.C., 657
- Makawiti, D.W., 311
- Martinez, M., 61
- Martínez-Frías, M.L., 173
- Mastroiacovo, P., 173
- Mattos, C.E.R., 473
- McCarthy, T., 473
- McEwan, J.A., 639
- McKenzie, L., 505
- McLaurin, V.L., 489
- McMullen, S.L., 31
- McNeilly, A.S., 89
- Meng, Y-X, 73
- Menjivar, M., 45
- Midiwo, J.O., 311
- Mishell, D.R., Jr., 473
- Moggia, A.V., 31
- Moggia, M.S., 31
- Mooij, P.N.M., 277
- Moo-Young, A.J., 393
- Mutchinick, O., 173
- Nash, H.A., 385
- Norman, J.E., 89
- Notelovitz, M., 505
- Nwadiani, K., 83
- Odland, V., 481
- Oehninger, S., 657
- Ogedengbe, O.K., 83
- Olsson, S-E, 481
- Otolorin, E.O., 163
- Pahwa, G.S., 549
- Parra, A., 541
- Patel, K.L., 453
- Pavez, M., 393, 473, 481
- Pelissier, C., 599
- Pérez-Palacios, G., 61
- Pike, M.C., 289
- Pitaktesombati, P., 623
- Porcile, A., 533
- Prihadi, S.M., 141
- Pulcrano, J., 125
- Puri, C.P., 245
- Ramírez, A., 541
- Ramos, I., 45
- Rebar, R.W., 1
- Robbins, M., 141
- Robert, E., 173
- Royston, P., 125
- Rubin, J., 217
- Saad, S., 419
- Sanchez-Nuncio, R., 61
- Sastrawinata, S., 141
- Setty, B.S., 461
- Severi, F.M., 155
- Shaaraway, M., 419
- Shah, R.S., 245
- Shahani, S.M., 453
- Sharma, S.C., 549
- Sheth, A.R., 559
- Shi, W., 367
- Shihata, A.A., 11
- Shoupe, D., 289, 473
- Sivin, I., 473, 481
- Smith, K.B.
- Socolsky, R., 235
- Soper, D.E., 21
- Spicer, D.V., 289
- Spieler, J., 125
- Stern, J., 473, 481
- Sunjoto, 141
- Tang, G.W.K., 523
- Thevenin, F., 473
- Thomas, C.M.G., 277
- Trussell, J., 11
- Tsong, Y.Y., 385
- Usifoh, C., 83
- Vadigoppula, A.D., 245
- Valencia, H., 541
- Valles de Bourges, V., 61
- Vanni, A.L., 155
- Vernekar, V.J., 245
- Virutamasen, P., 73
- Wagdi, A., 419
- Wahyudi, I., 141
- Wang, J., 367
- Wild, R.A., 113
- Wu, W.X., 89
- Xu, R., 367
- Zhu, P., 367
- Zeserson, K., 1
- Zutshi, U., 549

SUBJECT INDEX

Volume 44

June-December 1991

- Abutilon indicum, effect on uterine peroxidase activity (rat), 549
- Acceptability study, use of female condom, 183
- Acceptance, sterilization, 623
- Advised birth control system, diaphragm tampon applied to ovulation method, 607
- Antibodies generated by β -hCG vaccine, response to hCG stimulation test, 453
- Antide,
 effect on hormonal levels (monkey), 667
 effect on ovulation (monkey), 667
 effect on pregnancy (rat), 209
 LHRH antagonist, 209, 667
 pharmacokinetics (monkey), 667
- Antifertility activity, volatile fraction of neem oil (rat, rabbit, monkey), 319
- Antifertility effects, immunization with human sperm antigen (rat), 559
- At-risk populations, effect of ethinyl estradiol + norethindrone, 505
- Billings Ovulation Method, with use of diaphragm tampon, 607
- Binding affinities, various progestogens, 1
- Bioavailability, norethindrone (monkey), 327
- Biodegradable implant, Capronor^R, 409
- Biological activity, effect of new progestogens, 1
- Biological profile, CDRI-85/287 (rat), 461
- Bioself 110,
 electronic fertility indicator, 125
 use as a contraceptive aid, 125
- Bleeding pattern,
 use of depot-norethisterone enanthate, 639
 use of estradiol valerate + norethisterone enanthate, 589
 use of estradiol/progesterone formulation, 45
 use of 3-keto-desogestrel, 393
 use of levonorgestrel, 409
 use of norgestrel, 31
- Blood pressure,
 effect of levonorgestrel, 223
 effect of norethisterone, 223
- Bone metabolism, effect of GnRHAs, 289
- Breastfeeding pattern, use of norgestrel, 31
- Butea monosperma, effect on uterine peroxidase activity (rat), 549
- Cancer risk estimates, proposed GnRHA contraceptive regimen, 289
- Capronor^R, clinical trial of biodegradable implant, 409

CONTRACEPTION

- Carbohydrate metabolism,
 - effect of depo-medroxyprogesterone acetate, 419
 - effect of levonorgestrel, 163, 232
 - effect of new progestogens, 1
 - effect of norethisterone, 223
 - effect of norethisterone enanthate, 419
- CDRI-85/287 (2-(4-(2-N-piperidinoethoxy)phenyl)-3-phenyl (2H) benzo (b) pyran,
 - contraceptive activity (rat), 461
 - effect on pregnancy (rat), 461
 - effect on uterus (rat, rabbit), 461
- Centchroman, effect on uterine peroxidase activity (rat), 549
- Cervical cap, comparison to Fem Cap, 11
- Cervical mucus, effect of intranasal norethisterone, 245
- 6-Chloro-6-deoxyglucose,
 - antifertility activity, 649
 - effect on spermatozoa (rat, boar), 649
- Clinical parameters,
 - effect of ethinyl estradiol + norethindrone, 113
 - effect of ethinyl estradiol + norethindrone acetate, 113
 - effect of spironolactone, 113
- Clinical trial,
 - estradiol valerate + norethisterone enanthate, 589
 - Fem Cap, 11
 - 3-keto-desogestrel implants, 393
 - levonorgestrel biodegradable implant, 409
- Clomiphene citrate, effect on uterine peroxidase activity (rat), 549
- Coagulation, effect of new progestogens, 1
- Coagulation factors,
 - effect of depo-medroxyprogesterone acetate, 431
 - effect of depot-norethisterone enanthate, 639
 - effect of levonorgestrel, 223
 - effect of norethisterone, 223
- Coagulation function, effect of norethisterone enanthate, 73
- Coagulation regulatory system, effect of IUDs, 367
- Condom, female,
 - acceptability study, 183
 - clinical study, 21
- Contraceptive activity, CDRI-85/287 (rat), 461
- Contraceptive aid, Bloself 110 electronic fertility indicator, 125
- Contraceptive choice, following contraceptive failure, 83
- Contraceptive failure, outcome of pregnancy and subsequent contraceptive choice, 83
- Contraceptive practices, sexual habits and fertility patterns, community-based study, 445
- Contraceptive regimen using GnRHA, 289
- Copper release from IUDs, effect of tarnish, 385
- Copper T 220, effect on endometrium, 367
- Copper T 380A, clinical trial, 141
- Copper T 380Ag, seven-year clinical study, 473

- Copper-releasing IUDs, review article, 573
- Copper-T IUDs,
 - clinical study, 481
 - review of literature, 341
- Delaying menses, use of ethinylestradiol + desogestrel, 107
- Depo-medroxyprogesterone acetate,
 - effect on carbohydrate metabolism, 419
 - effect on coagulation factors, 431
 - effect on hormonal profile, 419
 - effect on lipid metabolism, 61, 431
 - serum level following administration, 61
- Desogestrel, characteristics, 1
- Diaphragm, clinical study, 21
- Diaphragm tampon,
 - Gynaeseal, 607
 - used with Billings Ovulation Method, 607
- Discontinuation, use of biodegradable levonorgestrel implants, 409
- Discontinuation rates and reasons,
 - ethinyl estradiol + norethindrone, 489
 - mestranol + norethindrone, 489
- Embelin (2,5-dihydroxy-3-undecyl-1,4-benzoquinone),
 - effect on uterine peroxidase activity (rat), 549
 - mode of action (male rabbit), 311
- Endometrial bleeding, effect of norethisterone enanthate, 73
- Endometrial histology, effect of norethisterone enanthate, 73
- Endometrial morphology, effect of intranasal norethisterone, 245
- Endometrium, effect of IUDs, 367
- Estradiol level, effect of estradiol/progesterone administration, 45
- Estradiol valerate + norethisterone enanthate,
 - clinical trial, 589
 - effect on lipid metabolism, 235
- Estradiol/progesterone sustained release formulation, effect on ovulation, 45
- Estrogenic/antiestrogenic potential of antifertility substances, effect on uterine peroxidase activity (rat), 549
- Ethinylestradiol + desogestrel,
 - ability to postpone withdrawal bleeding, 107
 - effect on hypothalamo-pituitary axis, 155
 - maintenance of remission of hirsutism, 533
- Ethinyl estradiol + gestodene, effect on lipid metabolism, 235
- Ethinyl estradiol + norethindrone,
 - clinical study, 489
 - effect on lipid metabolism in at-risk populations, 505
 - rates and reasons for discontinuation, 489
 - treatment for hirsutism, 113
- Ethinyl estradiol + norethindrone acetate, treatment for hirsutism, 113

CONTRACEPTION

- Failed contraception, outcome of pregnancy and subsequent contraceptive choice, 83
- Family planning aid, Bioself 110 electronic fertility indicator, 125
- Fem Cap,
 - clinical trial, 11
 - intravaginal barrier contraceptive device, 11
- Female condom, Femshield, 183
- Female condom (RealityTM),
 - effect on lower genital tract, 21
 - effect on resident bacterial flora, 21
 - effect on vaginal mucosa and/or vulvar skin, 21
- Female sterilization,
 - acceptance and regret, 623
 - physicians' attitudes, recommendations and practice, 191
- FemshieldTM,
 - acceptability, 183
 - vaginal sheath, 183
- Fertility indicator, Bioself 110 electronic device, 125
- Fertility patterns, contraceptive practices and sexual habits, community-based study, 445
- Folliculogenesis, effect of intranasal norethisterone, 245
- FSH (follicle stimulating hormone)
- FSH level, effect of estradiol/progesterone administration, 45
- Fucidin,
 - effect on spermatozoa, 657
 - effect on zona pellucida-sperm interaction, 657
- Gestodene, characteristics, 1
- GnRHA (gonadotrophin-releasing hormone agonist)
- GnRHA contraceptive regimen, cancer risk estimates, 289
- Gonadotrophin-releasing hormone agonist (GnRHA),
 - effect on bone metabolism, 289
 - effect on lipid metabolism, 289
 - effect on ovarian function, 289
 - use in proposed contraceptive regimen, 289
- Gynaeseal, diaphragm tampon, 607
- Gyne T 380, clinical study, 481
- Gyne T 380 Slimline, clinical study, 481
- hCG stimulation test, response of women immunized with β -hCG vaccine, 453
- β -hCG vaccine, study on antibodies produced, 453
- Hemostatic parameters, effect of norgestrel acetate, 599
- Hirsutism,
 - maintenance of remission with ethinyl estradiol + desogestrel, 533
 - treatment with ethinyl estradiol + norethindrone, 113
 - treatment with ethinyl estradiol + norethindrone acetate, 113
 - treatment with spironolactone, 113
- Hirsutism score, effect of ethinyl estradiol + desogestrel, 533

- Hormonal levels,
 - effect of antide (monkey), 667
 - effect of depo-medroxyprogesterone acetate, 419
 - effect of ethinylestradiol + desogestrel, 155
 - effect of ethinyl estradiol + norethindrone, 113
 - effect of ethinyl estradiol + norethindrone acetate, 113
 - effect of intranasal norethisterone, 245
 - effect of 3-keto-desogestrel, 393
 - effect of norgestrel acetate, 599
 - effect of norethisterone enanthate, 73, 419
 - effect of spironolactone, 113
 - effect of treatment with neem oil (monkey), 319
- Hypospadias in infants, association to maternal oral contraceptive use, 173
- Hypothalamo-pituitary axis, effect of ethinylestradiol + desogestrel, 155
- Immunization with sperm antigen, effect on fertility (rat), 559
- Implant contraceptive,
 - Capronor^R, 409
 - 3-keto-desogestrel, 393
 - levonorgestrel, 163, 217, 409
 - norethindrone acetate (monkey), 327
- Infant development, use of norgestrel in lactating women, 31
- Infant hypospadias, association to maternal oral contraceptive use, 173
- Injectable contraceptive,
 - depo-medroxyprogesterone acetate, 61, 419, 431
 - estradiol valerate + norethisterone enanthate, 235, 589
 - estradiol/progesterone sustained release formulation, 45
 - norethisterone enanthate, 73, 419, 639
- Insertion procedure, Norplant^R, 217
- Intestinal complication, five years after Nova-T insertion, 517
- Intranasal administration, norethisterone, 245
- Intrauterine device (IUD),
 - copper T 220, 367
 - Copper T 380A, 141, 385, 573
 - copper T 380Ag, 473, 573
 - copper-T devices, 341
 - effect of tarnish on copper release, 385
 - Gyne T 380, 481
 - Gyne T 380 Slimline, 481
 - levonorgestrel-releasing, 341, 367, 473, 573
 - Lippes C, 235
 - Lippes Loop D, 141
 - Multiload Cu 375, 141
 - multiload devices, 341
 - Nova-T, 235, 341, 517, 573
 - progesterone-releasing, 341
 - stainless steel ring, 367
 - TCu-200B, 573

CONTRACEPTION

- TCu-220C, 573
- TCu-380, 541
- Intravaginal barrier contraceptive device, Fem Cap, 11
- IUD (intrauterine device)
 - 3-Keto-desogestrel implants, clinical trial, 393
 - 3-Keto-desogestrel level, during use of 3-keto-desogestrel implants, 393
- Levonorgestrel,
 - effect on carbohydrate metabolism, 163
 - metabolic effects, 223
- Levonorgestrel biodegradable implant, clinical trial, 409
- Levonorgestrel-releasing IUD,
 - advantages of use, 573
 - disadvantages of use, 573
 - effect on endometrium, 367
 - performance, 573
 - review article, 573
 - review of literature, 341
 - seven-year clinical study, 473
 - traits comparable to copper-releasing IUDs, 573
- LH (luteinizing hormone)
- LH level,
 - effect of embelin (male rabbit), 311
 - effect of estradiol/progesterone administration, 45
- LHRH (luteinizing hormone-releasing hormone)
- LHRH antagonist, antide, 209, 667
- Lipid metabolism,
 - effect of depo-medroxyprogesterone acetate, 431
 - effect of estradiol valerate + norethisterone enanthate, 235
 - effect of ethinyl estradiol + desogestrel, 533
 - effect of ethinyl estradiol + gestodene, 235
 - effect of ethinyl estradiol + norethindrone, 505
 - effect of GnRHAs, 289
 - effect of 3-keto-desogestrel, 393
 - effect of levonorgestrel, 223
 - effect of Lippes C, 235
 - effect of new progestogens, 1
 - effect of norethisterone, 223
 - effect of Nova T, 235
- Lipoprotein metabolism, effect of depo-medroxyprogesterone acetate, 61
- Lippes C, effect on lipid metabolism, 235
- Lippes Loop D, clinical trial, 141
- Long-term intrauterine contraception,
 - levonorgestrel and copper T 380Ag IUDs, 473
 - serious intestinal complication after Nova-T insertion, 517
- Lower genital tract,
 - effect of diaphragm, 21
 - effect of female condom, 21
- Male antifertility activity, 6-chloro-6-deoxyglucose (rat, boar), 649

- Male sterilization,
 - acceptance and regret, 623
 - physicians' attitudes, recommendations and practice, 191
- Menstrual cycle,
 - effect of intranasal norethisterone, 245
 - effect of norethindrone acetate (monkey), 327
- Mestranol + norethindrone,
 - clinical study, 489
 - rates and reasons for discontinuation, 489
- Metabolic effects,
 - use of ethinyl estradiol + norethindrone, 113
 - use of ethinyl estradiol + norethindrone acetate, 113
 - use of levonorgestrel, 223
 - use of nomegestrol acetate, 599
 - use of norethisterone, 223
 - use of spironolactone, 113
- Metabolism, effect of new progestogens, 1
- Metoclopramide-stimulated prolactin level, effect of TCu-380, 541
- Mifepristone (RU486), effect on prostaglandin synthesis and metabolism, 89
- Multiload Cu 375, clinical trial, 141
- Multiload IUDs, review of literature, 341
- Natural hormones estradiol/progesterone in sustained release system, use as injectable contraceptive, 45
- Neem oil, antifertility activity (rat, rabbit, monkey), 319
- New progestogens, characteristics in combination oral contraceptives, 1
- Nomegestrol acetate, effect on hormonal, metabolic and hemostatic parameters, 599
- Norethindrone, bioavailability (monkey), 327
- Norethindrone level, use of subdermal implants (monkey), 327
- Norethisterone,
 - effect on cervical mucus, 245
 - effect on endometrial morphology, 245
 - effect on folliculogenesis, 245
 - effect on hormonal levels, 245
 - effect on vaginal cytology, 245
 - metabolic effects, 223
- Norethisterone enanthate,
 - effect on blood coagulation factors and menstrual bleeding patterns, 639
 - effect on carbohydrate metabolism, 419
 - effect on coagulation function, 73
 - effect on endometrial bleeding, 73
 - effect on endometrial histology, 73
 - effect on hormonal profile, 419
 - effect on ovarian hormones, 73
- Norgestimate, characteristics, 1
- Norgestrel,
 - clinical trial, 31
 - effect on breastfeeding, 31

CONTRACEPTION

- Norplant^R,
 - comparison of insertion procedures, 217
 - effect on carbohydrate metabolism, 163
- Nova-T,
 - attributes, 341
 - effect on lipid metabolism, 235
 - epidemiologic considerations, 341
 - review of literature, 341
 - review of performance, 341, 573
 - serious intestinal complication five years after insertion, 517
 - service delivery considerations, 341
- ONO 802, prostaglandin analogue, 523
- Oral contraceptive,
 - ethinylestradiol + desogestrel, 107, 155, 533
 - ethinylestradiol + gestodene, 235
 - ethinyl estradiol + norethindrone, 113, 489, 505
 - ethinyl estradiol + norethindrone acetate, 113
 - levonorgestrel, 223
 - mestranol + norethindrone, 489
 - nomegestrol acetate, 599
 - norethisterone, 223
 - norgestrel, 31
- Oral contraceptive use, association to infant hypospadias, 173
- Oral contraceptives,
 - effect on vitamin status, 277
 - progestogen component of combination formulations, 1
- Ovarian function, effect of GnRHAs, 289
- Ovulation, effect of antide (monkey), 667
- Ovulation method of birth control, efficacy and acceptability, 607
- Performance, Nova-T, 341
- PG (prostaglandin)
- PGF_{2α} levels, in normal saline-induced abortions, 99
- Physicians' attitudes, recommendation and practice of male and female sterilization, 191
- Pituitary response, use of ethinylestradiol + desogestrel, 155
- Postponement of withdrawal bleeding, use of ethinylestradiol + desogestrel, 107
- Potency, various progestogens, 1
- Pregnancy,
 - effect of antide (rat), 209
 - effect of CDRI-85/287 (rat), 461
- Pregnancy outcome, following contraceptive failure, 83
- Premenopausal women, effect of ethinyl estradiol + norethindrone, 505
- Progesterone level,
 - effect of antide (rat), 209
 - effect of embelin (male rabbit), 311
 - effect of estradiol/progesterone administration, 45
 - effect of ST-1435, 269
 - response in women immunized with β -hCG vaccine, 453

- Progesterone-releasing IUD, review of literature, 341
 Progestogens, in combination oral contraceptives, 1
 Prolactin level, effect of TCu-380, 541
 Prolonged intrauterine contraception, levonorgestrel and copper T 380Ag IUDs, 473
 Prostaglandin analogue, ONO 802, 523
 Prostaglandin synthesis and metabolism, effect of RU486, 89
 RealityTM,
 effect on lower genital tract, 21
 female condom, 21
 Regret, following sterilization, 623
 Removals, use of 3-keto-desogestrel implants, 393
 Review paper, Nova-T IUD, 341
 RU486 (mifepristone)
 RU486 + ONO 802,
 acceptability as an abortion method, 523
 side effects during treatment, 523
 use for early termination of pregnancy, 523
 Saline-induced abortions, PGF_{2α} levels, 99
 Sexual habits, contraceptive practices and fertility patterns, community-based study, 445
 Side effects,
 use of biodegradable levonorgestrel implants, 409
 use of estradiol valerate + norethisterone enanthate, 589
 use of ethinyl estradiol + norethindrone, 489
 use of GnRHAs, 289
 use of IUDs, 141
 use of mestranol + norethindrone, 489
 use of Norplant^R, 217
 Smoking women, effect of ethinyl estradiol + norethindrone, 505
 Sperm antigen, potential for use as contraceptive vaccine (rat), 559
 Sperm antigen immunization, antifertility effects (rat), 559
 Spermatozoa,
 effect of 6-chloro-6-deoxyglucose (rat, boar), 649
 effect of fucoidin, 657
 Spironolactone, treatment for hirsutism, 113
 ST-1435 (16-methylene-17-acetoxy-19-nor-4-pregnene-3,20-dione), transdermal absorption, 269
 ST-1435 level, following transdermal application of ST-1435, 269
 Stainless steel ring, effect on endometrium, 367
 Sterilization,
 acceptance and regret, 623
 factors affecting choice, 623
 physicians' attitudes, recommendations and practice, 191
 Steroidal effects, various progestogens, 1
 Tarnish, effect on copper release from IUDs, 385
 TCU IUDs, review of performance, 573
 TCu-380, effect on prolactin levels, 541
 Termination events, comparative clinical trials of IUDs, 141

Termination of pregnancy, use of RU486 and ONO 802 in combination, 523

Testosterone level,
 effect of embelin (rabbit), 311
 effect of ethinyl estradiol + desogestrel, 533

Transdermal absorption, ST-1435, 269

Triphasic ethinylestradiol + gestodene, effect on lipid metabolism, 235

Tubal ligation, physicians' attitudes, recommendations and practice, 191

Uterine peroxidase activity, effect of antifertility substances (rat), 549

Uterine weight, effect of antifertility substances (rat), 549

Uterus, effect of CDRI-85/287 (rat, rabbit), 461

Vaccine contraceptive, β -hCG vaccine, 453

Vaginal bacterial flora,
 effect of diaphragm, 21
 effect of female condom, 21

Vaginal cytology, effect of intranasal norethisterone, 245

Vasectomy, physicians' attitudes, recommendations and practice, 191

Vitamin status, effect of oral contraceptives, 277

Vitamin supplementation, effect in oral contraceptive users, 277

Zona pellucida-sperm interaction. effect of fucoidin. 657

688

